NuCyRNA Therapeutics

NuCyRNA Therapeutics is a biotechnology company specializing in the development of circular RNA (circRNA) therapies for rare genetic and metabolic disorders. Founded by pioneers in the field of lysosomal storage diseases, the company utilizes a proprietary platform to design circRNA molecules that offer enhanced stability and prolonged protein expression compared to traditional linear mRNA. Its lead research program focuses on Pompe disease, aiming to deliver functional acid alpha-glucosidase (GAA) through a circRNA modality. NuCyRNA's technology is designed to reduce the frequency of administration and improve therapeutic outcomes for patients with chronic enzyme deficiencies. The company's approach leverages the unique structural properties of circular RNA to avoid cellular immune sensors and extend the half-life of the therapeutic payload.